发明名称 |
USE OF SERELAXIN TO REDUCE GDF-15 |
摘要 |
Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine known to be associated with adverse events in heart failure patients. The use of serelaxin has been shown to affect GDF-15 levels at baseline and decreases in GDF-15 levels over time. Measuring GDF-15 levels allows a healthcare provider to accurately predict pulmonary load in patients with pulmonary congestion. |
申请公布号 |
CA2952061(A1) |
申请公布日期 |
2015.12.17 |
申请号 |
CA20152952061 |
申请日期 |
2015.06.10 |
申请人 |
NOVARTIS AG |
发明人 |
PRESCOTT, MARGARET FORNEY;ZHANG, YIMING;DAHLKE, MARION;SEVERIN, THOMAS |
分类号 |
A61K38/22;A61M5/14;A61P9/00;A61P11/00 |
主分类号 |
A61K38/22 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|